Switching to nephrology starting on Slide 21. Q3 EPOGEN sales declined 15% due to lower net selling price, which is a function of our contractual pricing commitments with DaVita. Meanwhile Aranesp declined 5% year-over-year in Q3 driven by lower volume due to increased competition. We expect Aranesp's sales to continue to decline at a faster rate with both long-acting and short-acting competition in the U.S.